Drugs / GST-HG151
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05345964 Comparator | Mar 2022 → Mar 2023 | — | Fujian Cosunter Pharmaceutical Co. Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GST-HG151 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05345964 ↗ |
| Route | Oral | “Subjects will take GST-HG151 orally(once daily) on Day 1” NCT05345964 ↗ |